Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter Subscribe to newsletter
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Recent news and posts

Tags

Use tags to find relevant records
3D printed implants
Ablation methods
Allogeneic mesenchymal stem cells
Ambulatory ECG monitoring
Aortic abdominal aneurysm
Aortic root replacement
Arthroplasty
Arthroscopy
Assisted ventilation
Atherectomy
Austria
Autologous chondrocyte implantation
Automated external defibrillator
AV fistula
AV graft
Balloon kyphoplasty
Bariatric surgery
Baroreflex activation therapy
Barrett’s oesophagus
Belgium
Benign prostatic hyperplasia
Biopsy
Bone Conductive Hearing Device
Breast reconstruction
Bronchial thermoplasty
Burns
Caesarean section
Cancer
Capsule endoscopy
Carbon ion therapy
Cardiac ablation
Cardiac computer tomography
Cardiac pacemaker
Cardiac resynchronization therapy
Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Cardiovascular devices
Cardiovascular procedures
Carotid endarterectomy
Cataract
Cell therapy
Cholecystectomy
Chronic obstructive pulmonary disease
Chronic wounds
Clinical guidelines
Cochlear implants
Commissioning
Companion diagnostic tests
Computed tomography
Conditional reimbursement
Connected medical devices
Continuous glucose monitoring (CGM)
Coronary interventions
Coronary percutaneous revascularization procedures
Coronary procedures
Coronavirus
Coverage with evidence development (CED)
See all tags

Two new diagnostic codes were added to private reimbursement schedule in England in July/August 2018

The Clinical Coding and Schedule Development (CCSD) develops and maintains procedural and diagnostics nomenclature for private payers in England. Once codes are added to the Schedule, a rivate insurance company can develop reimbursement tariff for these procedures and tests.

The CCSD Group has approved the following diagnostic codes for publication to the CCSD Schedule in July/August with a recommended adoption date of 1st November 2018:

  • 18S rRNA gene and Sequencing (3545G)
  • ELA2 Cyclic Neutropenia Genetic Screen (3546G)

See full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

Tags
UK
Private health insurance
Reimbursement
In-vitro diagnostic tests

The latest related news

07
May 2025

Further extension of the Hybrid DRGs catalog in 2026 agreed upon in Germany

On April 30, 2025, the National Association of Statutory Health Insurance Physicians (KBV) announced that it had reached an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) on the further expansion of the Hybrid DRG catalog in 2026. The decision was made by the extended Evaluation Committee, as no consensus could be reached with the German Hospital Federation (DKG).
Read more
06
May 2025

Med Tech-related health technology assessments from NIHR in April 2025

In April 2025, the National Institute for Health and Care Research (NIHR) in England released five Med Tech-related assessments in its HTA Journal, which concerned the evaluation of prognostic models of metastasis in colorectal cancer, assessment of e-Health platform for low back pain and the results of the “CONtact TrAcing in Care homes using digital Technology” trial. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS, and informs NICE guidance.
Read more
05
May 2025

Recommendations about add-on reimbursement for medical devices in France in April 2025

The French National Authority for Health (HAS) released new recommendations regarding add-on reimbursement for medical devices and medical aids following the April 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Eleven favorable opinions were published concerning the registration of new devices or modifying conditions/indications for existing ones in the List of Reimbursable Products and Services (LPPR). The recommendations relate to devices in the fields of endocrine, e-health, neuromodulation, peripheral vascular, and medical aids.
Read more
02
May 2025

Funding of 80 million SEK in 2025 for the Genomic Medicine Sweden (GMS) project

On April 14, 2025, the National Board of Health and Welfare was tasked to allocate 80 million SEK from the government to support Genomic Medicine Sweden (GMS) project in 2025. Funding will be distributed to several projects, including the development and/or implementation of innovative technologies such as whole genome sequencing based on long DNA reads, gene panels for sensitive detection of residual disease, and precision diagnostics (liquid biopsies for solid tumors, detection of antibiotic resistance).
Read more
01
May 2025

Med Tech-related technology assessments from NICE in April 2025

In April 2025, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance (Balloon disimpaction of the baby’s head during the cesarean section) and two Early Value Assessments (Robot-assisted surgery for soft tissue and orthopedic procedures). Furthermore, one new clinical guideline was published, and one was updated.
Read more